Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: Auro Vaccines, a wholly owned step-down subsidiary of the Company, has today, March 5, 2025, terminated the License Agreement (entered on September 27, 2023) with Hilleman Laboratories Singapore, to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination. The Auro Vaccines is not a material subsidiary to the Company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. It may also be noted that this termination of Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, the company will keep the exchanges informed about the same and provide necessary disclosures.
The above information is a part of company’s filings submitted to BSE.
